PACE

PROVIDER BULLETIN

September 6, 2002

Remodulin™

Effective September 9, 2002, PACE will add Actelion Pharmaceutical's Remodulin™ (treprostinil) injection to the Program's drug file. Remodulin™ is a treatment for Pulmonary Arterial Hypertension (PAH) and has only been approved for this diagnosis.

Claims received for Remodulin™ must go through the PACE Program medical exception process to be considered for payment.

Providers are advised that all claims for Remodulin™ will deny with the NCPDP Reject Code 88, PACE Error 706, accompanied by the system response of "High Dose." This response is being used to direct providers to contact the PACE Program.

Before authorizing payment, PACE **must** receive:

- a written diagnosis by either FAX or mail confirming that Remodulin™ is being used for the FDA approved indication.
- confirmation from the provider that other prescription coverage has been billed (when/if applicable).

Providers may direct questions concerning the medical exception process to

Provider Services at 1-800-835-4080